3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the "Best Track Record in the CEIN incubators" award
The company receives the award for the Best Track Record in the CEIN incubators at the International Congress of High Impact Entrepreneurship
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the “Best Track Record in the CEIN incubators” award. This award recognizes the outstanding contribution of 3P, from its birth in the CEIN incubators in 2007 to its current position as a leader in process development and manufacturing of biologic drugs.
The award ceremony, held in a setting of international entrepreneurship, was attended by the distinguished Minister of Industry, Digital and Ecological Transition, Mikel Irujo, who personally presented the award to the CEO of 3P Biopharmaceuticals, Dámaso Molero.
From its modest beginnings in the CEIN incubators, 3P has charted a spectacular narrative as a pioneer in the production of therapeutic proteins in Spain and Europe. The bold vision of its CEO, backed by the impetus of Sodena, the University of Navarra and public and private support committed to business innovation, has propelled the company to a benchmark position in a highly demanding international market.
What started as a dream and a single employee is today an essential reference for biotechnology in Europe and a driving force for the growth of Navarra’s health sciences ecosystem. With a multidisciplinary team of more than 350 professionals from 20 countries, 3P serves clients globally and has expanded its international influence with the strategic opening of its first commercial office in the dynamic city of Boston, USA, one of the most important areas in the world in biotechnology.
Upon receiving the award, Dámaso Molero, expressed his gratitude: “This honor is a testament to the tireless effort and dedication of the entire 3P team. Without the unwavering support of CEIN and the 3P team since our early days, none of this would be possible. We have an attractive, exciting future and I hope that with the audacity that has characterized us, we can continue to be a reference for many other entrepreneurs for whom I ask the CEIN and Navarre’s institutions for maximum support”.
With a constant commitment to the forefront of biotechnology, 3P looks boldly to the horizon. The company announces plans for expansion at the European level and the continuation of strategic investments in the development of its facilities at the Mocholí Industrial Park in Noáin, thus consolidating its position as an undisputed leader and pioneer in the biotechnology industry. 3P’s story is far from coming to an end; rather, it is in an exciting chapter of limitless innovation and future conquests.
